Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.

中文翻译：

---

癌症护理连续体中的患者导航：系统评价和新兴文献概述

患者导航是一种克服障碍、减少差异、改善准入和结果的策略。本次总体审查的目的是识别、严格评估、综合和提供最佳的现有证据，为有关癌症连续体患者导航的政策和规划提供信息。检查癌症护理导航的系统评价在 Cochrane 对照试验中央登记册 (CENTRAL)、PubMed、Embase、护理和联合健康累积指数 (CINAHL)、Epistemonikos 和前瞻性系统评价登记册 (PROSPERO) 数据库以及2012年1月1日至2022年4月19日的灰色文献。数据由两位作者独立筛选、提取和评价。JBI 系统审查和研究综合批判性评估清单用于质量评估。还探讨了截至 2022 年 5 月 25 日的新兴文献，以捕获超出所纳入系统综述范围的已发表的主要研究。在确定的 2062 条独特记录中，包括 61 条系统评价。54 篇综述是定量或混合方法综述，报告癌症患者导航的有效性，其中 12 篇综述报告成本或成本效益结果。七项定性审查探讨了导航需求、障碍和体验。此外，还纳入了 2021 年以来发表的 53 项初步研究。患者导航可有效提高癌症筛查的参与度，并缩短从筛查到诊断以及从诊断到开始治疗的时间。新的证据表明，患者导航可以提高生存阶段的生活质量和患者对护理的满意度，并减少积极治疗和生存护理阶段的再入院率。姑息治疗的数据极其有限。美国的经济评估表明，筛查项目中的导航具有潜在的成本效益。